After three straight losses in federal court, plaintiffs suing Janssen Pharmaceuticals and Bayer over the blood thinner Xarelto won a hard-fought victory last week with a nearly $28 million verdict. The award breathes new life into the litigation, but with appeals likely and a new class of plaintiffs on the horizon, plaintiffs counsel aren’t expected to simply rinse, wash and repeat.

On Dec. 5, after nearly a month of trial, a Philadelphia jury awarded Lynn Hartman $27.8 million over claims that the defendants failed to adequately disclose the risk that patients on Xarelto would suffer a bleed. The case was the first bellwether trial for plaintiffs in state court after three federal juries—two juries in Louisiana and one in Mississippi—found for the drugmakers.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]